NIR-II 이미징 시스템 시장 : 세계 예측(2026-2032년)

The NIR-II Imaging System Market is projected to grow by USD 338.17 million at a CAGR of 10.13% by 2032.

NIR-II Imaging Systems: Executive Overview

Near-infrared-II (NIR-II) imaging systems operate within the longer-wavelength near-infrared range, commonly associated with approximately 1,000-1,700 nanometers. Their value proposition is based on reduced light scattering, lower tissue autofluorescence, and improved imaging clarity compared with shorter-wavelength optical approaches. These characteristics support applications in preclinical research, image-guided procedures, vascular visualization, biomedical diagnostics, and industrial or scientific sensing. Adoption depends on detector performance, illumination safety, contrast-agent development, workflow integration, regulatory pathways, and the availability of trained users.

From Laboratory Platforms to Integrated Imaging Workflows

The NIR-II imaging landscape is shifting from stand-alone experimental demonstrations toward more integrated systems that combine cameras, illumination modules, optics, software, and compatible contrast agents. Improvements in indium gallium arsenide and emerging sensor technologies are supporting greater sensitivity, faster acquisition, and more practical form factors. At the same time, researchers are emphasizing real-time visualization, multimodal imaging, quantitative analysis, and compatibility with established surgical or laboratory workflows. Progress remains constrained by component cost, calibration requirements, limited standardization, and the need for robust clinical evidence.

Artificial Intelligence Strengthens Image Interpretation and Workflow Efficiency

Artificial intelligence is increasingly relevant to NIR-II imaging through denoising, motion correction, image registration, segmentation, enhancement, and automated quantitative analysis. Machine-learning tools can help distinguish vessels, lesions, or labeled structures and may improve consistency when image quality varies across operators or systems. The strongest practical benefits are likely to come from AI embedded within acquisition and analysis workflows rather than from image enhancement alone. Reliable deployment requires representative training data, transparent validation, protection of patient information, management of algorithmic bias, and regulatory controls for software that influences clinical decisions.

Regional Insights: Uneven Adoption Shaped by Research Capacity and Regulation

North America benefits from substantial biomedical research infrastructure, advanced clinical centers, and established pathways for translational imaging development. Europe combines strong photonics and medical research capabilities with regulatory and reimbursement considerations that can lengthen adoption cycles. Asia-Pacific is supported by extensive electronics manufacturing, active university research, and growing investment in medical technology, although regulatory environments differ considerably across markets. Latin America is developing capabilities through academic and hospital partnerships, with access to specialized equipment and financing remaining important constraints. The Middle East is investing in advanced healthcare infrastructure and research hubs, while Africa's progress is concentrated in institutions able to support specialized imaging, training, maintenance, and clinical validation.

Group Insights: Collaboration Networks Influence Technology Diffusion

ASEAN markets present a mixed landscape in which leading urban medical centers and research institutions can serve as adoption nodes, while procurement and training conditions vary across members. BRICS countries contribute diverse manufacturing, research, and healthcare capabilities, but differences in regulation, infrastructure, and access affect implementation. The European Union benefits from cross-border research collaboration and common regulatory structures, alongside demanding evidence and compliance requirements. G7 members generally combine advanced imaging research with sophisticated healthcare systems and strong data-governance expectations. GCC countries are building specialized healthcare and research capacity through coordinated investment, while NATO members may benefit from broader collaboration in optics, sensing, imaging software, and dual-use technical expertise without implying a common commercial pathway.

Country Insights: Capabilities Range from Component Strength to Clinical Translation

Australia supports NIR-II research through universities, medical institutes, and specialized biomedical programs. Brazil and Mexico are developing adoption through leading hospitals and academic partnerships, with equipment access and technical support influencing progress. Canada and the United States combine strong research ecosystems with active translational and clinical development. China, Japan, and South Korea contribute significant capabilities in sensors, electronics, photonics, and biomedical research. India offers a large scientific and healthcare base, while implementation varies by institution. France, Germany, Italy, Spain, and the United Kingdom contribute expertise in photonics, medical imaging, and clinical research, with evidence requirements shaping deployment. Russia retains relevant scientific and engineering capabilities, although collaboration, procurement, and access to advanced components can be affected by external constraints.

Actionable Priorities for Leaders: Validate Use Cases Before Scaling

Industry leaders should begin with clearly defined clinical, research, or industrial problems where NIR-II provides a measurable advantage over existing imaging methods. Product development should prioritize modular systems, intuitive workflows, interoperable data formats, reliable calibration, and serviceability in the intended operating environment. Partnerships with hospitals, universities, contrast-agent developers, detector specialists, and software teams can accelerate validation while reducing integration risk. Leaders should also establish evidence plans early, covering safety, reproducibility, usability, cybersecurity, and regulatory classification. AI features should be introduced with documented performance boundaries, human oversight, and monitoring for drift across devices, populations, and operating conditions.

Research Methodology: Evidence-Led Assessment of Technology and Adoption Conditions

This executive summary uses a structured assessment of NIR-II imaging-system characteristics, including wavelength behavior, detector and illumination technologies, imaging applications, workflow requirements, AI capabilities, regional infrastructure, and regulatory considerations. Insights are synthesized from established technical principles and publicly observable patterns in biomedical imaging, photonics, healthcare delivery, and research commercialization. Geographic discussion reflects differences in research capacity, manufacturing ecosystems, healthcare infrastructure, procurement conditions, and policy environments. The assessment intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific claims, and should be supplemented with primary interviews and jurisdiction-specific regulatory review for investment or commercialization decisions.

Conclusion: Practical Integration Will Determine NIR-II Imaging Progress

NIR-II imaging systems offer a compelling platform for applications requiring deeper optical penetration, improved contrast, and quantitative visualization, but technical promise alone will not ensure broad adoption. Progress will depend on dependable hardware, validated contrast agents, clinically meaningful workflows, interoperable software, and evidence that demonstrates benefits over established alternatives. Regional and country-level differences make flexible deployment models essential. Leaders that combine disciplined use-case selection with rigorous validation, responsible AI integration, workforce development, and long-term service support will be best positioned to translate NIR-II capabilities into durable scientific and healthcare value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. NIR-II Imaging System Market, by Product Type

• 7.1. Introduction
• 7.2. Components
  • 7.2.1. Contrast Agent
    • 7.2.1.1. Organic Dyes
    • 7.2.1.2. Quantum Dots
    • 7.2.1.3. Rare Earth Nanoparticles
  • 7.2.2. Controller Unit
  • 7.2.3. Detector
    • 7.2.3.1. InGaAs Camera
    • 7.2.3.2. Photomultiplier Tube
  • 7.2.4. Laser Source
    • 7.2.4.1. Diode Lasers
    • 7.2.4.2. Fiber Lasers
• 7.3. Software
• 7.4. Systems

8. NIR-II Imaging System Market, by Deployment

• 8.1. Introduction
• 8.2. Ex Vivo
• 8.3. In Vitro
• 8.4. In Vivo

9. NIR-II Imaging System Market, by Application

• 9.1. Introduction
• 9.2. Clinical Diagnostics
• 9.3. Drug Discovery
• 9.4. Preclinical Research
  • 9.4.1. Cellular Imaging
  • 9.4.2. Whole Animal Imaging
• 9.5. Surgical Imaging

10. NIR-II Imaging System Market, by End User

• 10.1. Introduction
• 10.2. Academic And Research Institutions
• 10.3. Contract Research Organizations
• 10.4. Hospitals And Diagnostic Centers
• 10.5. Pharmaceutical And Biotech Companies

11. NIR-II Imaging System Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. NIR-II Imaging System Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. NIR-II Imaging System Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Andor Technology Ltd.
• 15.2. Bruker Corporation
• 15.3. Bruker Nano GmbH
• 15.4. Cheetah Technologies Pvt. Ltd.
• 15.5. Cobalt Light Systems Ltd.
• 15.6. Excelitas Technologies Corp.
• 15.7. FLIR Systems, Inc.
• 15.8. Fluoptics SA
• 15.9. Hamamatsu Photonics America, LLC
• 15.10. Hamamatsu Photonics K.K.
• 15.11. Horiba Ltd.
• 15.12. Laser Components GmbH
• 15.13. LI-COR Biosciences, Inc.
• 15.14. Nanonics Imaging Ltd.
• 15.15. NIRx Medical Technologies, Inc.
• 15.16. NIRx Medical Technologies, LLC
• 15.17. Optronis GmbH
• 15.18. PerkinElmer, Inc.
• 15.19. Photon Etc.
• 15.20. Photon Focus AG
• 15.21. Photonetc Inc.
• 15.22. Princeton Instruments, Inc.
• 15.23. QSI Imaging, LLC
• 15.24. Raptor Photonics Ltd.
• 15.25. Simphotek Co., Ltd.
• 15.26. Teledyne e2v
• 15.27. Vieworks Co., Ltd.
• 15.28. Xenics nv

16. Key Experts